LIVE

TWST

Twist Bioscience Corporation

TWST

NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $6.4B

$99.21

▼ -2.98%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$23.30 - $105.47

P/E

-77.50

Fwd P/E

-71.96

Beta

2.21

Div Yield

0.00%

Avg Vol

1.7M

Shares Out

61.3M

Mkt Cap

$6.4B

Price action

Price chart

Up 171.4% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • Proprietary silicon chip-based DNA synthesis platform enabling superior cost and speed efficiency
  • Scalable manufacturing technology with significant barriers to entry and replication
  • Strategic partnerships with major pharmaceutical companies validating technology and driving adoption
  • Diversified product portfolio spanning drug discovery, diagnostics, and emerging data storage markets
  • First-mover advantage in synthetic DNA manufacturing with established intellectual property portfolio
▼

Bear Case

1 risk

  • High volatility (beta 2.2). Larger-than-normal price swings expected.

Growth

Strong growth ahead

Expanding adoption of synthetic biology in pharmaceutical R&D and personalized medicine

Value

Deep value opportunity - significant discount to Life Sciences Tools peers

Momentum

Hot

+103.6% over 3m

Quality

Strong

Excellent business quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 3, 2026

“
Q2 26 RECAP

MAY 4, 2026

Reported EPS of -$0.71 vs -$0.49 consensus (-44.9% surprise). Revenue of $110.7M vs $107.6M expected (+2.9%).

EPS miss
Rev beat +2.9%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-44.9%

Next: Aug 3, 2026

Revenue trend · last 8Q

—

—

—

+24%

+23%

+18%

+17%

+17%

Q2 24

Q3 24

Q4 24

Q1 24

Q2 25

Q3 25

Q4 25

Q1 25

$75.3M

$81.5M

$84.7M

$88.7M

$92.8M

$96.1M

$99.0M

$103.7M

Margins · last 8Q

Gross

52.0%

Operating

-31.7%

Profit

-29.4%

View full earnings history →

Wall Street consensus

7 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

7

100%

Hold

0%

Sell

0%

Median Price Target

$65.00

▼ -34.5% vs $99.21

Low $55.00
Median $65.00
High $107.00

Latest: Guggenheim · $107.00 · Jun 29, 2026

4 analysts covering

View full analyst page →

vs Industry

How TWST stacks vs Medical - Diagnostics & Research

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.